A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity

被引：1
|
作者：
Cohen, S. J.
Zalupski, M. M.
Modiano, M. R.
Conkling, P. R.
Patt, Y. Z.
Davis, P.
Dorr, R. T.
Boytim, M. L.
Hersh, E. M.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Arizona Oncol Associates, Tucson, AZ USA
[4] Virgina Oncol Associates, Norfolk, VA USA
[5] Univ New Mexico, Albuquerque, NM 87131 USA
[6] Univ Arizona, Tucson, AZ USA
[7] Amplimed Corp, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4619
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
    Borad, Mitesh J.
    Bai, Li-Yuan
    Richards, Donald
    Mody, Kabir
    Hubbard, Joleen
    Rha, Sun Young
    Soong, John
    McCormick, Daniel
    Tse, Emmett
    O'Brien, Daniel
    Bayat, Ahmad
    Ahn, Daniel
    Davis, S. Lindsey
    Park, Joon Oh
    Oh, Do-Youn
    HEPATOLOGY, 2023, 77 (03) : 760 - 773
  • [42] A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Kim, Ho Gak
    Noh, Myung Hwan
    Lee, Sang Hyub
    Kim, Yong-Tae
    Kim, Hyo Jung
    Kim, Chang Duck
    Lee, Dong Ki
    Cho, Kwang Bum
    Cho, Chang Min
    Moon, Jong Ho
    Kim, Dong Uk
    Kang, Dae Hwan
    Cheon, Young Koog
    Choi, Ho Soon
    Kim, Tae Hyeon
    Kim, Jae Kwang
    Moon, Jieun
    Shin, Hye Jung
    Song, Si Young
    MEDICINE, 2017, 96 (01)
  • [43] Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain: Results from phase 3 study AB12005.
    Ezenfis, Joel
    Hermine, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
    Imaoka, H.
    Sasaki, M.
    Ueno, M.
    Ozaka, M.
    Kobayashi, S.
    Fukushima, T.
    Furukawa, T.
    Ikeda, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1484 - S1484
  • [45] Phase I study of combination of pasireotide LAR plus gemcitabine in locally advanced or metastatic pancreatic cancer
    Suleiman, Yaman
    Mahipal, Amit
    Shibata, David
    Siegel, Erin M.
    Jump, Helen
    Fulp, William J.
    Springett, Gregory M.
    Kim, Richard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (03) : 481 - 487
  • [46] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    R D Kim
    S R Alberts
    C Peña
    I Genvresse
    A Ajavon-Hartmann
    C Xia
    A Kelly
    J E Grilley-Olson
    British Journal of Cancer, 2018, 118 : 462 - 470
  • [47] GEMCITABINE (GEM) PLUS CELECOXIB IN ADVANCED PANCREATIC CANCER: A PHASE II STUDY
    Valcamonico, F.
    Ferrari, V. D.
    Simoncini, E.
    Amoroso, V.
    Vassalli, L.
    Rangoni, G.
    Grisanti, S.
    Marpicati, P.
    Marini, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [48] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470
  • [49] Gemcitabine plus dose-escalated epirubicin in advanced breast cancer:: results of a phase I study
    Lüftner, D
    Flath, B
    Akrivakis, C
    Hans-Günther, M
    Ohnmacht, U
    Arning, M
    Possinger, K
    INVESTIGATIONAL NEW DRUGS, 1998, 16 (02) : 141 - 146
  • [50] Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study
    Diana Lüftner
    Bernd Flath
    Costa Akrivakis
    Hans-Günther Mergenthaler
    Ute Ohnmacht
    Michael Arning
    Kurt Possinger
    Investigational New Drugs, 1998, 16 : 141 - 146
12345